Skip to main
BTSG

BTSG Stock Forecast & Price Target

BTSG Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 54%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrightSpring Health is positioned for growth in both its Pharmacy Solutions and Provider Services segments, with a diverse customer base and a focus on complex patients. Its financial strength is evident in its consistent revenue growth and strong margins, and its utilization of technology and data-driven solutions bodes well for its future success in the evolving healthcare industry. Additionally, its strategic acquisitions and partnerships show a commitment to expanding its service offerings and reaching new markets.

Bears say

BrightSpring Health is facing headwinds in their internal growth due to a decline in Medicare memberships and a slowdown in the specialty business. Additionally, rising costs of raw materials and the potential for changes in healthcare policy could negatively impact their operations. While the company has shown strength in M&A activity and has a strong pipeline of drugs converting to generics, they remain highly leveraged, and their reliance on payors for revenue leaves them vulnerable to reimbursement rate changes. Furthermore, their significant PE ownership could generate pricing pressure. Overall, with stagnant internal growth outlook and potential risks in the industry, it is prudent to have a negative outlook on BrightSpring Health's stock.

BTSG has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 54% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BrightSpring Health Services Inc (BTSG) Forecast

Analysts have given BTSG a Buy based on their latest research and market trends.

According to 13 analysts, BTSG has a Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BrightSpring Health Services Inc (BTSG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.